Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Choline fenofibrate
Cat. No.:
0225LY-0921
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Choline fenofibrate is a choline-based formulation of fenofibrate that acts as a prodrug and phenoxy-isobutyric acid derivative with antihyperlipidemic activity.
Synonym:
Trilipix; ABT-335; 856676-23-8; 2-Hydroxy-N,N,N-trimethylethanaminium 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate; Fenofibrate de choline; Fenofibric acid choline salt; Fibricor; ABT 335; 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate;2-hydroxyethyl(trimethyl)azanium; 2-Hydroxy-N,N,N-trimethylethanaminium 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
CAS No.:
856676-23-8
Compound CID:
11350701
Formula:
C22H28ClNO5
Formula Weight:
421.91
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Choline fenofibrate can be used in clinical pharmacology to study the management of severe hypertriglyceridemia and mixed dyslipidemia.
Library Information
Target:
COX; PPAR; P450
Receptor:
COX; PPAR; P450
Pathways:
Immunology/Inflammation; Metabolism; DNA damage/DNA repair; Neuronal signaling
Plate Number:
AOCL-12
Plate Location:
h2
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
4.22 mg/mL; 10 mM
ALogP:
1.111
HBA_Count:
2
HBD_Count:
1
Rotatable Bond:
7
